Recent findings from a retrospective cohort study conducted within the Division of Hematology and Oncology at the Perelman School of Medicine, University of Pennsylvania found no difference in overall survival between fixed 2-year vs. indefinite duration front-line treatment with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Following extensive analysis of 1091 patients on ICI treatment 2 years after diagnosis, overall survival from 760 days was 79% in the fixed-duration group compared to 81% in the infinite duration group. The study authors therefore determined there was no statistically significant difference in overall survival and thus determined that their study "supports treatment discontinuation at 2 years as a valid approach that does not appear to compromise survival outcomes."
To read more about this study, click here.
Sources mentioned:
Sun L, Bleiberg B, Hwang W-T, et al. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer. JAMA Oncology; Published online 4 June 2023. doi:10.1001/jamaoncol.2023.1891
West H(J). Clinical Decision Making in the Real World—The Perfect as the Enemy of the Good. JAMA Oncology; Published online 4 June 2023. doi:10.1001/jamaoncol.2023.1811
No comments:
Post a Comment